Revolutionizing Drug Discovery: The Role of Artificial Intelligence and Machine Learning.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges.Pharmaceuticals (Basel, Switzerland) · 2026
   Review
2. Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
   Review
3. Artificial intelligence in drug development: reshaping the therapeutic landscape.Therapeutic advances in drug safety · 2025
   Review
4. New antibiotics targeting Gram-negative bacilli.Le infezioni in medicina · 2025
   Review
5. The Use of AI for Phenotype-Genotype Mapping.Methods in molecular biology (Clifton, N.J.) · 2025
   Article
6. Computational Landscape in Drug Discovery: From AI/ML Models to Translational Application.Scientifica · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as